TABLE 2.
Baseline characteristics of cancer patients with COVID-19.
| Total (N = 112), No. (%) | Alive (N = 94), No. (%) | Death (N = 18), No. (%) | p value | |
|---|---|---|---|---|
| Age, median (IQR), year | 62.95±15.70 | 62.85±15.80 | 63.44±15.66 | 0.884 |
| Sex | ||||
| Female | 52 (46.4) | 46 (48.9) | 6 (33.3) | 0.224 |
| Male | 60 (53.6) | 48 (51.1) | 12 (66.7) | |
| Tumor nature | ||||
| Solid tumor | 90 (80.4) | 76 (80.9) | 14 (77.8) | >0.99 |
| Non-Solid tumor | 22 (19.6) | 18 (19.1) | 4 (22.2) | |
| Tumor diagnosis | ||||
| Lung cancer | 23 (20.5) | 20 (21.3) | 3 (16.7) | 0.9 |
| Breast cancer | 11 (9.8) | 11 (11.7) | 0 (0) | 0.273 |
| Leukemia | 11 (9.8) | 10 (10.6) | 1 (5.6) | 0.817 |
| Colon cancer | 10 (8.9) | 10 (10.6) | 0 (0) | 0.318 |
| Liver cancer | 9 (8.0) | 7 (7.4) | 2 (11.1) | 0.96 |
| Gastric cancer | 6 (5.4) | 2 (2.1) | 4 (22.2) | 0.006 |
| Thyroid cancer | 7 (6.3) | 6 (6.4) | 1 (5.6) | >0.99 |
| Cervical cancer | 4 (3.6) | 4 (4.3) | 0 (0) | >0.99 |
| Rectum cancer | 4 (3.6) | 4 (4.3) | 0 (0) | >0.99 |
| Myeloma | 5 (4.5) | 4 (4.3) | 1 (5.6) | >0.99 |
| Lymphoma | 4 (3.6) | 3 (3.2) | 1 (5.6) | 0.509 |
| Bladder cancer | 5 (4.5) | 5 (5.3) | 0 (0) | >0.99 |
| Pancreatic cancer | 1 (0.9) | 0 (0) | 1 (5.6) | 0.161 |
| Nasopharynx cancer | 2 (1.8) | 2 (2.1) | 0 (0) | >0.99 |
| Ovarian cancer | 2 (1.8) | 2 (2.1) | 0 (0) | >0.99 |
| Myelodysplastic syndrome | 2 (1.8) | 1 (1.1) | 1 (5.6) | 0.297 |
| Prostate cancer | 2 (1.8) | 1 (1.1) | 1 (5.6) | 0.297 |
| Esophageal cancer | 1 (0.9) | 1 (1.1) | 0 (0) | >0.99 |
| Oral Cancer | 1 (0.9) | 0 (0) | 1 (5.6) | 0.161 |
| Meningioma | 1 (0.9) | 1 (1.1) | 0 (0) | >0.99 |
| Osteosarcoma | 1 (0.9) | 1 (1.1) | 0 (0) | >0.99 |
| Laryngeal cancer | 1 (0.9) | 1 (1.1) | 0 (0) | >0.99 |
| Penile cancer | 1 (0.9) | 1 (1.1) | 0 (0) | >0.99 |
| Skin cancer | 1 (0.9) | 0 (0) | 1 (5.6) | 0.161 |
| Comorbidities | ||||
| Number of Comorbidities per patient >2 | 27 (24.1) | 17 (18.1) | 10 (55.6) | 0.002 |
| Hypertension | 33 (29.5) | 29 (30.9) | 4 (22.2) | 0.462 |
| Common pulmonary infection | 4 (3.6) | 2 (2.1) | 2 (11.1) | 0.121 |
| Diabetes | 20 (17.9) | 19 (20.2) | 1 (5.6) | 0.249 |
| Chronic lung disease | 10 (8.9) | 7 (7.4) | 3 (16.7) | 0.42 |
| Cardiovascular disease | 10 (8.9) | 7 (7.4) | 3 (16.7) | 0.42 |
| Chronic bronchitis | 8 (7.1) | 5 (5.3) | 3 (16.7) | 0.225 |
| Hepatitis | 7 (6.3) | 6 (6.4) | 1 (5.6) | >0.99 |
| Cerebrovascular disease | 4 (3.6) | 2 (2.1) | 1 (11.1) | 0.121 |
| Arrhythmia | 4 (3.6) | 2 (2.1) | 2 (11.1) | 0.121 |
| Anemia | 5 (4.5) | 3 (3.2) | 2 (11.1) | 0.182 |
| Pleural effusion | 4 (3.6) | 2 (2.1) | 2 (11.1) | 0.121 |
| Hypoproteinemia | 4 (3.6) | 2 (2.1) | 2 (11.1) | 0.121 |
| Abnormal thyroid function | 1 (0.9) | 1 (1.1) | 0 (0) | >0.99 |
| Gastritis | 3 (2.7) | 1 (1.1) | 2 (11.1) | 0.067 |
| Chronic kidney disease | 3 (2.7) | 1 (1.1) | 2 (11.1) | 0.067 |
| Cancer treatment (<28 days) | ||||
| Chemotherapy | 12 (10.7) | 7 (7.4) | 5 (27.8) | 0.032 |
| Radiotherapy | 4 (3.6) | 2 (2.1) | 2 (11.1) | 0.121 |
| Surgery | 8 (7.1) | 6 (6.4) | 2 (11.1) | 0.83 |
| Targeted therapy | 4 (3.6) | 3 (3.2) | 1 (11.1) | 0.509 |
| Severity of COVID-19 | ||||
| Moderate | 14 (12.5) | 14 (14.9) | 0 (0) | <0.001 |
| Severe | 58 (51.8) | 58 (61.7) | 0 (0) | |
| Critical | 40 (35.7) | 22 (13.4) | 18 (100.0) | |
P values a indicate differences between surviving patients and non-surviving patients; P < 0.05 was considered statistically significant.